ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Gary L. Grunkemeier
Ruyun Jin
Albert Starr
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grunkemeier, G. L.
Right arrow Articles by Starr, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grunkemeier, G. L.
Right arrow Articles by Starr, A.
Related Collections
Right arrowRelated Articles

Ann Thorac Surg 2006;82:776-780
© 2006 The Society of Thoracic Surgeons

The statistician's page

Prosthetic Heart Valves: Objective Performance Criteria Versus Randomized Clinical Trial

Gary L. Grunkemeier, PhD, Ruyun Jin, MD*, Albert Starr, MD

Providence Health System, Portland, Oregon

* Address correspondence to Dr Jin, 9155 SW Barnes Rd, LL Suite 33, Portland, OR 97225 (Email: ruyun.jin{at}providence.org).

The current Food and Drug Administration (FDA) heart valve guidance document uses an objective performance criteria (OPC) methodology to evaluate the clinical performance of prosthetic heart valves. OPC are essentially historical controls, but they have turned out to be an adequate, and perhaps optimal, study design in this situation. Heart valves have a simple open-and-close mechanism, device effectiveness is easy to document, and the common complications (thromboembolism, thrombosis, bleeding, leak, and infection) are well known and easily detected. Thus, randomized clinical trials (RCTs) have not been deemed necessary for the regulatory approval of prosthetic heart valves. The OPC are derived from the average complication rates of all approved heart valves. Studies based on OPC have been shown to work well; many different valve models have gained FDA market approval based on this methodology. Although heart valve RCTs are not required by the FDA, they have been done to compare valves or treatment regimens after approval. Recently, the Artificial Valve Endocarditis Reduction Trial (AVERT) was designed to compare a new Silzone sewing ring, designed to reduce infection, with the Standard sewing ring on a St. Jude Medical heart valve. This was the largest heart valve RCT ever proposed (4,400 valve patients, followed for as long as 4 years), but it was stopped prematurely because of a high leak rate associated with the Silzone valve. Examining the results showed that a much smaller, OPC-based study with 800 patient-years would have been sufficient to disclose this complication of the Silzone valve.


Related Articles

Progress Versus Precision: Challenges in Clinical Trial Design for Left Ventricular Assist Devices
Michael K. Parides, Alan J. Moskowitz, Deborah D. Ascheim, Eric A. Rose, and Annetine C. Gelijns
Ann. Thorac. Surg. 2006 82: 1140-1146. [Abstract] [Full Text] [PDF]

FDA Perspective on Clinical Trial Design for Cardiovascular Devices
Eric Chen, Wolf Sapirstein, Chul Ahn, Julie Swain, and Bram Zuckerman
Ann. Thorac. Surg. 2006 82: 773-775. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
N. Piazza, A. Asgar, R. Ibrahim, and R. Bonan
Transcatheter Mitral and Pulmonary Valve Therapy
J. Am. Coll. Cardiol., May 19, 2009; 53(20): 1837 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
P. T.L. Chiam and C. E. Ruiz
Percutaneous Transcatheter Aortic Valve Implantation: Assessing Results, Judging Outcomes, and Planning Trials: The Interventionalist Perspective
J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 341 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
A. Vahanian, O. R. Alfieri, N. Al-Attar, M. J. Antunes, J. Bax, B. Cormier, A. Cribier, P. De Jaegere, G. Fournial, A. P. Kappetein, et al.
Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 1 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Vahanian, O. Alfieri, N. Al-Attar, M. Antunes, J. Bax, B. Cormier, A. Cribier, P. De Jaegere, G. Fournial, A. P. Kappetein, et al.
Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Eur. Heart J., June 1, 2008; 29(11): 1463 - 1470.
[Abstract] [Full Text] [PDF]

Home page
 Card Surg AdultHome page
R. F. Padera Jr. and F. J. Schoen
Pathology of Cardiac Surgery
Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
E. Chen, W. Sapirstein, C. Ahn, J. Swain, and B. Zuckerman
FDA perspective on clinical trial design for cardiovascular devices.
Ann. Thorac. Surg., September 1, 2006; 82(3): 773 - 775.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The Society of Thoracic Surgeons.